Related Experiment Videos
Adjuvant treatment for rectal cancer: current status
S Schneebaum1, M W Arnold, E W Martin
1Division of Surgical Oncology, Ohio State University, Columbus.
Oncology (Williston Park, N.Y.)
|March 1, 1993
Summary
Rectal cancer treatment combines surgery with radiation and chemotherapy. Recent studies indicate that 5-fluorouracil (5-FU) with radiation may be as effective as investigational agents, with preoperative approaches showing promise.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Surgery is the primary curative treatment for rectal cancer.
- Adjuvant therapy for TNM stages II and III rectal cancer typically involves postoperative radiation and chemotherapy.
- Established regimens include 5-fluorouracil (5-FU) and semustine (methyl-CCNU) with radiation, though 5-FU alone is emerging as an alternative.
Purpose of the Study:
- To evaluate the efficacy of different treatment modalities for rectal cancer.
- To explore the potential benefits of preoperative radiotherapy compared to postoperative approaches.
- To identify areas for future research in optimizing rectal cancer treatment strategies.
Main Methods:
- Review of existing studies on rectal cancer treatment protocols.
- Analysis of outcomes for patients receiving postoperative chemoradiation (5-FU, semustine).
- Assessment of preoperative radiation therapy, including its combination with 5-FU and the role of rectal ultrasound in staging.
Main Results:
- Preliminary data suggest radiation with 5-FU alone is an effective substitute for combined-agent therapy.
- Preoperative radiation offers advantages over postoperative radiotherapy, potentially mitigated by rectal ultrasound for staging.
- Combined preoperative radiation and 5-FU show promise as a radiosensitizer with systemic effects.
Conclusions:
- Radiation with 5-FU is a viable adjuvant treatment for rectal cancer.
- Preoperative chemoradiation is a promising strategy requiring further investigation.
- Future research should focus on less toxic radiosensitizers, novel chemotherapy combinations (e.g., levamisole), and optimal treatment sequencing.